Tevogen Bio Delays Latest Quarterly Filing with SEC

Dow Jones11-16

By Sabela Ojea

Tevogen Bio said it is delaying the publication of its filing third-quarter filing with the Securities and Exchange Commission, citing material weaknesses in its internal controls over financial reporting.

The biotechnology company on Friday said the delay follows a recent change in the third party firm in charge of a portion of its internal accounting and financing reporting.

Overall for the third quarter, the company expects to post a loss of about $4.3 million for the first nine months of 2024, down from a loss of $56.8 million for the same period a year earlier.

The news come a day after founder and Chief Executive Ryan Saadi suggested the company needed to raise capital.

"Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution," Saadi said. "Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share."

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

November 15, 2024 17:26 ET (22:26 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483839531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-16 06:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483839531","market":"sh","top_or_hot":-1,"title":"Tevogen Bio Delays Latest Quarterly Filing with SEC","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Tevogen Bio said it is delaying the publication of its filing third-quarter filing with the Securities and Exchange Commission, citing material weaknesses in its internal controls over financial reporting. \n</p>\n<p>\n  The biotechnology company on Friday said the delay follows a recent change in the third party firm in charge of a portion of its internal accounting and financing reporting. \n</p>\n<p>\n  Overall for the third quarter, the company expects to post a loss of about $4.3 million for the first nine months of 2024, down from a loss of $56.8 million for the same period a year earlier. \n</p>\n<p>\n  The news come a day after founder and Chief Executive Ryan Saadi suggested the company needed to raise capital. \n</p>\n<p>\n  \"Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution,\" Saadi said. \"Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share.\" \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 15, 2024 17:26 ET (22:26 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tevogen Bio Delays Latest Quarterly Filing with SEC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTevogen Bio Delays Latest Quarterly Filing with SEC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 06:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sabela Ojea \n\n\n \n\n\n  Tevogen Bio said it is delaying the publication of its filing third-quarter filing with the Securities and Exchange Commission, citing material weaknesses in its internal ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483839531","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483839531","pubTimestamp":1731709560,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Tevogen Bio said it is delaying the publication of its filing third-quarter filing with the Securities and Exchange Commission, citing material weaknesses in its internal controls over financial reporting.The biotechnology company on Friday said the delay follows a recent change in the third party firm in charge of a portion of its internal accounting and financing reporting.Overall for the third quarter, the company expects to post a loss of about $4.3 million for the first nine months of 2024, down from a loss of $56.8 million for the same period a year earlier.The news come a day after founder and Chief Executive Ryan Saadi suggested the company needed to raise capital.\"Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution,\" Saadi said. \"Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TVGN":"Tevogen Bio Holdings"},"translate_title":"Tevogen Bio推迟向SEC提交最新季度文件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVGN":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Tevogen Bio said it is delaying the publication of its filing third-quarter filing with the Securities and Exchange Commission, citing material weaknesses in its internal controls over financial reporting. \n\n\n  The biotechnology company on Friday said the delay follows a recent change in the third party firm in charge of a portion of its internal accounting and financing reporting. \n\n\n  Overall for the third quarter, the company expects to post a loss of about $4.3 million for the first nine months of 2024, down from a loss of $56.8 million for the same period a year earlier. \n\n\n  The news come a day after founder and Chief Executive Ryan Saadi suggested the company needed to raise capital. \n\n\n  \"Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution,\" Saadi said. \"Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share.\" \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 15, 2024 17:26 ET (22:26 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483839531"}